Institution
AIDS Clinical Trials Group
Nonprofit•Boston, Massachusetts, United States•
About: AIDS Clinical Trials Group is a nonprofit organization based out in Boston, Massachusetts, United States. It is known for research contribution in the topics: Didanosine & Maintenance therapy. The organization has 90 authors who have published 66 publications receiving 4099 citations.
Topics: Didanosine, Maintenance therapy, Zidovudine, Viral load, Saquinavir
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Inflammatory-mediated inhibition of cytochrome P450 3A may have been attenuated due to atazanavir-associated increases of bilirubin, which has known anti-inflammatory properties.
Abstract: BackgroundInflammation is associated with the down-regulation of drug metabolizing enzymes and transporters. Thus, we investigated the chronic inflammatory state associated with HIV infection as a ...
5 citations
••
TL;DR: This review will provide a summary of these areas while exploring PK considerations for ARVs, DAAs, and addiction treatment medications.
Abstract: There are many factors that can affect the pharmacokinetics (PK) of drugs. Pathophysiological changes from disease states can alter the mechanisms that control the PK of antiretrovirals (ARVs), direct-acting antivirals (DAAs), and addiction treatment medications. Drug-drug interaction pathways of certain ARVs and DAAs can be very complex, with agents being substrates, inhibitors, or inducers of multiple metabolic and transporter pathways. Buprenorphine and methadone may be used in HIV- and hepatitis C virus (HCV)-infected patients and may also be affected by drug interactions. Current research is focused on novel PK analyses, which aim to describe the PK of agents within organs that host the infection of interest, such as within hepatocytes during treatment for HCV. Modeling techniques allow for the prediction of drug PK in specific organs and the plasma compartment. This review will provide a summary of these areas while exploring PK considerations for ARVs, DAAs, and addiction treatment medications.
5 citations
••
University of North Carolina at Chapel Hill1, AIDS Clinical Trials Group2, Silver Spring Networks3, University of Washington4, Johns Hopkins University5, University of California, Riverside6, University of California, San Francisco7, Harvard University8, University of California, San Diego9, Brigham and Women's Hospital10
TL;DR: The AIDS Clinical Trials Group (ACTG) A5345 study as discussed by the authors included an intensively monitored antiretroviral pause (IMAP), during which a cohort of participants temporarily stopped antireto-viral treatment during chronic HIV infection.
Abstract: The AIDS Clinical Trials Group (ACTG) A5345 study included an intensively monitored antiretroviral pause (IMAP), during which a cohort of participants temporarily stopped antiretroviral treatment during chronic HIV infection. We surveyed participant perceptions and understanding of A5345 using a cross-sectional sociobehavioral questionnaire. Participants completed the baseline questionnaire either before or after initiating the study's IMAP. Questionnaire responses were linked to existing demographic data. Quantitative responses were analyzed overall and stratified by IMAP status. Open-ended responses were analyzed using conventional content analysis. Thirty-two participants completed the baseline sociobehavioral questionnaire. Half (n = 16) completed it before (i.e., pre-IMAP initiation group) and half (n = 16) after IMAP initiation (i.e., post-IMAP initiation group). Eight pre-IMAP initiation respondents (50%) and 11 post-IMAP respondents (69%) responded "yes" when asked if they perceived any direct benefits from participating in A5345. Perceived societal-level benefits included furthering HIV cure-related research and helping the HIV community. Perceived personal-level benefits included the opportunity to learn about the body's response to IMAP and financial compensation. The majority of respondents-13 from each group (81% of each)-reported risks from participation, for example, viral load becoming detectable. A5345 participants perceived both societal- and personal-level benefits of study participation. While the majority of survey respondents perceived participatory risks, nearly one in five did not. Key messages pertaining to study-related risks and benefits may need to be clarified or reiterated periodically throughout follow-up in HIV cure-related studies with IMAPs. Clinical Trail Registration Number: NCT03001128.
4 citations
••
TL;DR: Only LDL cholesterol was significantly higher in the cord blood of PI-exposed infants versus those not exposed to PIs in utero, and the clinical relevance of the effect of maternal PI treatment on infant LDL cholesterol levels at birth is not clear.
Abstract: BackgroundTo investigate the effect of exposure to protease inhibitor (PI) therapy in utero on cord blood lipids in infants born to mothers enrolled in AIDS Clinical Trials Group protocol 5084, a p...
4 citations
••
TL;DR: GenePro, a therapeutic vaccine candidate, has shown preclinical efficacy via publicly sponsored research that demonstrates the potential to address a current therapeutic issue.
Abstract: Despite advances in HIV commercial therapies, including fixed-dose combinations, unprecedented proportions of HIV patients remain without therapeutic options due to lack of access to treatment and epidemiologically significant proportions of multi-class drug resistance that are driving morbidity levels in both developed and resource-poor settings. The need to emphasize the development of therapeutic options with the potential to abrogate these correlating trends are receiving insufficient dedication of resources, as new clinical strategies do not address these enduring disparities. GenePro, a therapeutic vaccine candidate, has shown preclinical efficacy via publicly sponsored research that demonstrates the potential to address a current therapeutic issue.
2 citations
Authors
Showing all 90 results
Name | H-index | Papers | Citations |
---|---|---|---|
Michael S. Saag | 110 | 480 | 62247 |
Thomas C. Merigan | 98 | 514 | 33941 |
Martin S. Hirsch | 82 | 322 | 32239 |
Robert W. Shafer | 77 | 276 | 21133 |
Margaret A. Fischl | 72 | 258 | 27639 |
Alan Forrest | 63 | 282 | 14625 |
Gregory K. Robbins | 52 | 127 | 12285 |
Janet Andersen | 51 | 136 | 10648 |
Roland L. Bassett | 47 | 308 | 11802 |
Hulin Wu | 45 | 158 | 6353 |
Gene D. Morse | 39 | 236 | 5837 |
John S. Lambert | 38 | 195 | 4739 |
Mary Culnane | 24 | 33 | 9626 |
Qing Ma | 23 | 104 | 1757 |
Robin DiFrancesco | 20 | 57 | 1093 |